August 17, 2026

Obesity Runners-Up Behind Lilly-Novo, Aleniglipron 16.3% ACCESS II, Biogen Felzartamab China NMPA, Frontiers AMP Cancer Review

Obesity runners-up (Structure, Amgen, Pfizer) chase Lilly-Novo. Aleniglipron 16.3%. Biogen felzartamab China approval. Frontiers AMP cancer review.

4 stories · Covering industry, clinical-trials, research

Editor's Note

Monday's peptide news is anchored on obesity runner-up positioning heading into the 2027-2028 Phase 3 showdown behind Eli Lilly and Novo Nordisk. Seoul Economic Daily published Monday August 17 a market synthesis on the obesity drug runner-up field with Structure Therapeutics (NASDAQ: GPCR), Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE), and others positioning for approval filings and market launches in 2027-2028. Structure Therapeutics anchored the runner-up narrative with the Phase 2b ACCESS II trial of aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist) documenting 16.3% placebo-adjusted mean weight loss at the 180 mg dose and 16.0% at the 240 mg dose at 44 weeks, positioning aleniglipron as the highest-efficacy oral GLP-1 agonist data reported to date and setting Structure up for Phase 3 initiation in H2 2026. Biogen (NASDAQ: BIIB) and Chinese partner TJ Biopharma announced that felzartamab (branded Jingfei in China, an anti-CD38 monoclonal antibody) has been approved by China's National Medical Products Administration (NMPA) for use with lenalidomide and dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. And Frontiers in Medicine's 2026 comprehensive review on antimicrobial peptides (AMPs) as cancer treatments and vaccines synthesizes the growing body of preclinical and early-clinical evidence for cationic amphipathic peptides that selectively target the negatively charged phospholipid outer leaflets of malignant cell membranes.

Industry

Seoul Economic Daily Published Monday August 17, 2026 a Market Synthesis on the Obesity Drug Runner-Up Field With Structure Therapeutics (NASDAQ: GPCR), Amgen (NASDAQ: AMGN, With MariTide Now Positioned as Sole Obesity Focus After Amgen Halted AMG 513 Development), Pfizer (NYSE: PFE, With Danuglipron Plus Metsera Pipeline), and Others Positioning for Approval Filings and Market Launches in 2027-2028 Behind Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) That Currently Dominate the Global Obesity Drug Market; The Sorting of Winners From Losers Based on Phase 3 Results Will Begin in Earnest Starting Next Year With Amgen Expected to Apply for MariTide Regulatory Approval in Late 2026 to Early 2027 and Structure Therapeutics Expected to Initiate Aleniglipron Phase 3 in H2 2026

Seoul Economic Daily published Monday August 17, 2026 a market synthesis on the obesity drug runner-up field. Key runners-up positioning for 2027-2028 approval filings behind Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO): Structure Therapeutics (NASDAQ: GPCR) with aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist) expected to initiate Phase 3 in H2 2026; Amgen (NASDAQ: AMGN) with MariTide (once-monthly injectable dual GIPR antagonist / GLP-1 agonist) now positioned as the sole obesity focus after the July 29 Q2 disclosure that Amgen halted AMG 513 Phase 1 development to concentrate resources on the MariTide MARITIME Phase 3 program; and Pfizer (NYSE: PFE) with danuglipron oral GLP-1 receptor agonist plus the Metsera acquisition pipeline. Amgen expects to apply for MariTide regulatory approval in late 2026 to early 2027. The Amgen MariTide Phase 3 program covers obesity (MARITIME-1) plus obesity and type 2 diabetes (MARITIME-2), with additional Phase 3 studies exploring cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea. The sorting of winners from losers based on Phase 3 results will begin in earnest starting next year as the field competes on efficacy, safety, delivery format, and price for market share behind Lilly's Zepbound-Mounjaro-Foundayo franchise and Novo's Wegovy-Ozempic franchise.

#obesity-runners-up #structure-therapeutics #gpcr #amgen #amgn #maritide #amg-513-halted #pfizer #pfe #danuglipron #metsera #eli-lilly #novo-nordisk #phase-3-showdown #2027-2028-filing-window

Clinical Trials

Structure Therapeutics (NASDAQ: GPCR) Anchored the Obesity Runner-Up Narrative With the Phase 2b ACCESS II Trial of Aleniglipron (Once-Daily Oral Small-Molecule GLP-1 Receptor Agonist) That Documented 16.3% Placebo-Adjusted Mean Weight Loss at the 180 mg Dose (39 lbs) and 16.0% Weight Loss at the 240 mg Dose (37 lbs) at 44 Weeks Positioning Aleniglipron as the Highest-Efficacy Oral GLP-1 Agonist Data Reported to Date; The Core Phase 2b ACCESS Study Had Documented 11.3% Weight Loss at 120 mg at 36 Weeks; ACCESS Open-Label Extension (OLE) Study Documented Continued Weight Loss From 36 Weeks Up to 16.2% (40.5 lbs) With 120 mg at 56 Weeks With No Observed Plateau; Tolerability Profile Consistent With the GLP-1 Class With Only 3.7% Adverse-Event-Related Treatment Discontinuation Across All Active Arms at 120 mg or Higher From Weeks 28 to 44; Phase 3 Initiation Expected in H2 2026

Structure Therapeutics (NASDAQ: GPCR) reported detailed Phase 2b ACCESS II trial results for aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist for obesity). Key efficacy: 16.3% placebo-adjusted mean weight loss at the 180 mg dose (39 lbs) and 16.0% weight loss at the 240 mg dose (37 lbs) at 44 weeks. This positions aleniglipron as the highest-efficacy oral GLP-1 agonist data reported to date, above Eli Lilly's orforglipron (Foundayo, 7.5-11.2% at 72 weeks in ATTAIN-1) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg, roughly 15% at 68 weeks in OASIS 4). The core Phase 2b ACCESS study had documented 11.3% placebo-adjusted weight loss at 120 mg at 36 weeks. The ACCESS Open-Label Extension (OLE) study documented continued weight loss from 36 weeks up to 16.2% (40.5 lbs) with 120 mg at 56 weeks with no observed plateau, an important tolerability and durability signal. Tolerability profile is consistent with the GLP-1 receptor agonist class with only 3.7% adverse-event-related treatment discontinuation across all active arms in participants who reached 120 mg or higher from weeks 28 to 44. Phase 3 initiation is expected in H2 2026. Aleniglipron is a non-peptide small molecule that binds the GLP-1 receptor, similar to Lilly's orforglipron but distinct from the peptide-based semaglutide and tirzepatide; the small-molecule format provides manufacturing scalability advantages over peptide APIs.

#structure-therapeutics #gpcr #aleniglipron #access-ii #oral-glp-1 #small-molecule-glp-1 #16-3-percent-weight-loss #phase-2b #phase-3-h2-2026 #orforglipron-comparison #no-plateau-56-weeks #3-7-percent-discontinuation

Industry

Biogen (NASDAQ: BIIB) and Chinese Partner TJ Biopharma Announced Monday August 17, 2026 That Felzartamab for Injection (Branded Jingfei in China) an Anti-CD38 Monoclonal Antibody Has Been Approved by China's National Medical Products Administration (NMPA) for Use With Lenalidomide and Dexamethasone in Adults With Multiple Myeloma Who Have Received at Least One Prior Line of Therapy; Felzartamab Represents an Alternative Anti-CD38 Mechanism to Sanofi's SARCLISA (Isatuximab) and J&J's DARZALEX (Daratumumab) That Have Anchored the Anti-CD38 Multiple Myeloma Commercial Segment; The China Approval Marks TJ Biopharma's First Regional Commercial Launch for Felzartamab and Extends the Biogen-China Partnership Approach for Both Ex-China Drug Development and In-China Commercial Positioning

Biogen (NASDAQ: BIIB) and Chinese partner TJ Biopharma announced Monday August 17, 2026 that felzartamab for injection (branded Jingfei in China), an anti-CD38 monoclonal antibody, has been approved by China's National Medical Products Administration (NMPA) for use with lenalidomide and dexamethasone in adults with multiple myeloma who have received at least one prior line of therapy. Anti-CD38 mechanism context: CD38 is a transmembrane glycoprotein highly expressed on multiple myeloma plasma cells and less on normal cells, making it a validated target for monoclonal antibody therapy. Felzartamab represents an alternative anti-CD38 mechanism to Sanofi's SARCLISA (isatuximab) and Johnson & Johnson's DARZALEX (daratumumab), the two commercial anti-CD38 monoclonal antibodies that have anchored the anti-CD38 multiple myeloma commercial segment since first approvals in 2015 (daratumumab) and 2020 (isatuximab). Felzartamab's specific differentiation lies in a distinct epitope-binding domain on CD38 that may translate to different infusion-reaction profiles and combination-therapy potential. The China NMPA approval marks TJ Biopharma's first regional commercial launch for felzartamab and extends the Biogen-China partnership approach for both ex-China drug development and in-China commercial positioning. Beyond multiple myeloma, felzartamab is being studied for anti-neutrophil cytoplasmic antibody-associated vasculitis (ANCA vasculitis), IgA nephropathy, and antibody-mediated kidney transplant rejection in ex-China trials that Biogen leads.

#biogen #biib #tj-biopharma #felzartamab #jingfei #anti-cd38 #monoclonal-antibody #multiple-myeloma #china-nmpa #regulatory-approval #sarclisa #darzalex #iga-nephropathy

Research

Frontiers in Medicine 2026 Comprehensive Review on Antimicrobial Peptides (AMPs) as Cancer Treatments and Vaccines Synthesizes the Growing Body of Preclinical and Early-Clinical Evidence for Cationic Amphipathic Peptides That Selectively Target the Negatively Charged Phospholipid Outer Leaflets of Malignant Cell Membranes to Produce Selective Cytotoxicity via Membrane Disruption Plus Intracellular Actions Including Inhibition of DNA Replication and Protein Synthesis, Induction of Mitochondrial Dysfunction, and Suppression of Tumor Angiogenesis; The Review Extends the AMP-Anticancer Research Trajectory Anchored by the August 7 Nature aMPC16-CA50 Membranolytic Peptide Study and Recent Frog-Skin AMP (Dermaseptins, Temporins, Brevinins) Coverage; Challenges Remaining Include High Toxicity at Effective Anticancer Doses, Poor Systemic Stability, Limited Cellular Penetration, and Costly Synthesis but the Mechanism Diversity Across Natural-Origin, Synthetic, and AI-Designed AMPs Continues to Expand

Frontiers in Medicine 2026 comprehensive review on antimicrobial peptides (AMPs) as cancer treatments and vaccines synthesizes the growing body of preclinical and early-clinical evidence. Mechanism synthesis: AMPs are cationic (positively charged) amphipathic (both water-loving and lipid-loving) peptides that selectively interact with the negatively charged phospholipid outer leaflets of malignant cell membranes (produced by higher phosphatidylserine externalization in cancer cells compared to normal cells). This selectivity produces cytotoxicity through membrane disruption, followed by intracellular actions including inhibition of DNA replication and protein synthesis, induction of mitochondrial dysfunction (opening the mitochondrial permeability transition pore to release cytochrome c and trigger apoptosis), and suppression of tumor angiogenesis (reducing tumor vascular supply). The review extends the AMP-anticancer research trajectory anchored by the August 7, 2026 Nature aMPC16-CA50 synthetic acid-responsive membranolytic peptide study and recent MDPI Antibiotics coverage of frog-skin AMP families (dermaseptins from Phyllomedusa frogs, temporins from Rana temporaria, brevinins from Rana and Sylvirana). Ongoing translation challenges include high systemic toxicity at effective anticancer doses (requiring tumor-selective delivery), poor systemic stability (peptidase degradation in blood), limited cellular penetration (large hydrophilic molecules), and costly synthesis (multi-step solid-phase peptide synthesis at gram-scale). Mechanism diversity across natural-origin, synthetic (using natural templates), and AI-designed AMPs (using machine learning to design novel sequences with optimized properties) continues to expand the therapeutic pipeline.

#antimicrobial-peptide #amp #anticancer-peptide #frontiers-medicine #cationic-amphipathic #membranolytic #phosphatidylserine #membrane-disruption #mitochondrial-dysfunction #tumor-angiogenesis #ai-designed-amp #dermaseptin #temporin #brevinin